Could a liver artery shot make cancer treatment more effective?
NCT ID NCT04544098
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether giving the drug Lutathera directly into the liver artery is safe and practical for people with neuroendocrine tumors that have spread mainly to the liver. Ten participants will receive two doses into the liver artery followed by two standard IV doses. Researchers will compare the two methods and check if the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lutathera (177Lu-DOTATATE)
- What this could lead to
- If this works, it could show a new way to deliver Lutathera that is more effective for liver tumors, potentially improving control of neuroendocrine cancer that has spread to the liver.
- What could go wrong
- This is a very early, small pilot study with only 10 people, so results may not apply widely. The treatment involves radiation and may cause side effects like liver damage or low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation